190P Palbociclib treatment in pre/perimenopausal women with advanced/metastatic breast cancer (ABC/mBC): Real-world patient characteristics, treatment patterns, and outcomes data from POLARIS

Palbociclib (PAL), in combination with an aromatase inhibitor (AI) as initial endocrine-based therapy (ET) or with fulvestrant (FUL), is indicated for the treatment of hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2–) ABC/mBC. This analysis describes real-world patient (pt) characteristics, treatment patterns, and preliminary tumour response in pre/perimenopausal women with HR+/HER2– ABC/mBC enrolled in the POLARIS study.